Low-Grade Ductal Carcinoma in situ Within a Fibroadenoma of the Breast: A Rare Case Report and Review of the Literature

Abstract

Background

Ductal carcinoma in situ within a breast fibroadenoma is a rare malignancy with an incidence of only 0.02–0.125%. Imaging of low-grade ductal carcinoma in situ within a breast fibroadenoma shows no specific presentation. Therefore, pathology and immunohistochemistry are required for definitive diagnosis. Surgery is currently considered to be an effective treatment. There is no uniform clinical standard for postoperative adjuvant radiotherapy.

Case Summary

A 60-year-old female patient underwent excisional biopsy on October 19, 2022. Pathology and immunohistochemistry confirmed the diagnosis of low-grade ductal carcinoma in situ within the fibroadenoma. Subsequently, breast-conserving surgery and sentinel lymph node biopsy were performed under general anesthesia with tracheal intubation, and no cancer metastasis was observed in the sentinel lymph nodes or incisional margins.

Conclusion

Low-grade ductal carcinoma in situ within a breast fibroadenoma is an extremely rare malignancy, and clinicians should be familiar with its clinicopathological features and treatment methods. Multidisciplinary joint treatment is recommended to maximize the benefits to patients.

Keywords:

• breast
• fibroadenoma
• ductal carcinoma in situ
• case report
• review of the literature

Abbreviations

FA, Fibroadenoma; US, Ultrasound; MMG, Mammography; FNAC, Fine needle aspiration cytology; CNB, Core needle aspiration biopsy; BCS, Breast-conserving surgery; NSM, Nipple-sparing mastectomy; SSM, Skin-sparing mastectomy; VNPI, Van Nuys prognostic index.

Ethical Approval

Institutional approval was not required to publish the case details.

Consent for Publication

Written informed consent was obtained from the patient for publication of this paper and any accompanying images.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to OncoTargets and Therapy, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This study was supported by Weifang Health and Family Planning Commission (wfwsjs_2018_029).